Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Authors
Keywords
-
Journal
TRANSFUSION MEDICINE AND HEMOTHERAPY
Volume 44, Issue 5, Pages 327-336
Publisher
S. Karger AG
Online
2017-09-08
DOI
10.1159/000479980
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulating IgG effector function by Fc glycan engineering
- (2017) Tiezheng Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
- (2017) Tim Wirt et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
- (2016) Brant A. Inman et al. CLINICAL CANCER RESEARCH
- An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
- (2016) S P Koerner et al. LEUKEMIA
- Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
- (2016) Marco Thomann et al. MOLECULAR IMMUNOLOGY
- A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
- (2016) Rob N. de Jong et al. PLOS BIOLOGY
- Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
- (2015) Isaak Quast et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors
- (2015) Daniela Kao et al. Cell Reports
- IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions
- (2014) William Kelton et al. CHEMISTRY & BIOLOGY
- U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2014) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients
- (2013) C Kellner et al. LEUKEMIA
- Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity
- (2013) Stefanie Derer et al. mAbs
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Antibody-Based Immunotherapy of Cancer
- (2012) Louis M. Weiner et al. CELL
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- Marketed therapeutic antibodies compendium
- (2012) Janice M. Reichert mAbs
- Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc receptor engagement
- (2012) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies
- (2012) Ryan Haryadi et al. Bioengineered
- Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
- (2011) S. Veeramani et al. BLOOD
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
- (2011) Tsunehiro Mizushima et al. GENES TO CELLS
- The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
- (2011) P. Boross et al. HAEMATOLOGICA
- Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo
- (2011) Markus Biburger et al. IMMUNITY
- Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
- (2011) Roland Repp et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose
- (2011) C. Ferrara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
- (2010) S. de Haij et al. CANCER RESEARCH
- Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase
- (2010) H. H. von Horsten et al. GLYCOBIOLOGY
- Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
- (2010) Wei Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Engineering host cell lines to reduce terminal sialylation of secreted antibodies
- (2010) Michael F. Naso et al. mAbs
- Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system
- (2009) Patrick H.C. van Berkel et al. BIOTECHNOLOGY AND BIOENGINEERING
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
- (2009) S.-Y. Wang et al. BLOOD
- Optimization of Fc-mediated effector functions of monoclonal antibodies
- (2009) William R Strohl CURRENT OPINION IN BIOTECHNOLOGY
- Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils
- (2009) Mami Shibata-Koyama et al. EXPERIMENTAL HEMATOLOGY
- Structure of the Murine Unglycosylated IgG1 Fc Fragment
- (2009) Matthias J. Feige et al. JOURNAL OF MOLECULAR BIOLOGY
- Monoclonal antibodies for cancer immunotherapy
- (2009) Louis M Weiner et al. LANCET
- Glycosylation as a strategy to improve antibody-based therapeutics
- (2009) Roy Jefferis NATURE REVIEWS DRUG DISCOVERY
- Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
- (2008) M. Peipp et al. BLOOD
- Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
- (2008) D. Dayde et al. BLOOD
- The impact of Fc engineering on an anti-CD19 antibody: increased Fc receptor affinity enhances B-cell clearing in nonhuman primates
- (2008) J. Zalevsky et al. BLOOD
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Terminal sugars of Fc glycans influence antibody effector functions of IgGs
- (2008) T Shantha Raju CURRENT OPINION IN IMMUNOLOGY
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now